Working… Menu

A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00431340
Recruitment Status : Terminated (Terminated due to dose limiting toxicity)
First Posted : February 5, 2007
Last Update Posted : July 8, 2015
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : June 2007
Actual Study Completion Date : June 2007